AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance
AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance The Globe and Mail
Covered in this story
Analyst targets on Amgen
- Oppenheimer: $439 → $480 by Oct 2027 · Outperform via Investing.com India
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 14 Jul 2026.
Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.